A 13-minute shock. The value of "Bundle Fairy Rope"

The A-share market continued to rise this week, the Shanghai Composite Index rebounded to record highs.　　Among them, the Bio-medicine unit has soared, Sea King biological to yesterday afternoon close before 13 minutes, this week has been pulled out 4 consecutive trading, in its drive, the Tamiflu gene, the Temple of Heaven Biology, PLO shares and other vaccine-subject stocks have strengthened. But yesterday afternoon, the situation suddenly changed: 14:46, Sea King living in the vast number of the maintenance of a single word to continue trading; 14:47, selling a single suddenly gathered, with a number of consecutive 2 million-share sales of a single hit out, 14:48, the stock trading was opened, the share price was quickly hit to only rise 3.92　　%; With the resolute and unremitting efforts of the selling list, the unit is to be collected by green plate. Sea King biological close 13 minutes before the sharp fluctuations, triggering the medical unit of the "Earthquake", the gene and so on are diving at the same time, medicine from the "arrogant" into a mourning.　　Analysts believe that the recent sharp shocks in pharmaceutical stocks, fully explained that no matter in any environment, investors should hold a cautious speculation on the subject-matter stocks, after all, the value of this investment Market "bundle Fairy Rope" the power, who also can not tell when will unfold.　　Subject speculation on the recent strength of pharmaceutical stocks, there is a point of view that the early growth of pharmaceutical stocks lag behind, in the prevention of disease level of the background, the Fund began to intervene in the medical unit, and from the excavation of the Temple of Heaven Biology and other biological medicine stocks, thus activating the entire plate. But there is also the view that the recent rise in pharmaceutical stocks, purely subject to speculation. On the one hand because the performance of bio-medicine unit such as Rhine Biology and Sea King Biology is not so good that some people in the industry are mean to say that, in addition to individual stocks, the medical unit which wears biological two-word abbreviation will not profit more than 1 cents per share. Although it is a bit absolute, it is true that the accounting statements of the Bio-medicine unit have been checked.　　On the other hand, it is because of the level of the epidemic, but the relevant listed companies to improve the likelihood of performance is not, just as the 2003 SARS concept stock speculation eventually ended up with a feather like. In this respect, the author is inclined to the latter, that is, the current pharmaceutical stocks, especially the bio-pharmaceutical stocks rise, is a typical theme hype, future stock prices may be similar to the current SARS concept stocks. On the one hand, because of the accumulation of technology and experience, the epidemic will eventually be suppressed, on the other hand, because a lot of bio-medicine stocks are purely the trend of speculation, the level of the epidemic is merely an excuse for speculation, rather than performance promotion accelerator, so, again violent subject matter, again fierce speculation, it is difficult to break through the value of gravity, Just like a man can't leave the earth with his own hair. Therefore, the author believes that in the near period of time, the bio-pharmaceutical stock speculation must be cooled.　　This weekend's plunge in the Bio-medicine unit has led to a simultaneous cooling of the entire pharmaceutical stock market. Not chasing a strong stock This also gives investors a revelation, that is, try not to chase the so-called "strong stocks." After all, on the basis of no substantial changes in fundamentals, the higher the FRY, the deeper the fall. Stocks such asThis, as well as the market. And for a stock, once too high to go down the altar, then, it is very likely to usher in a long adjustment road, the year of the Shanghai Pudong Concept Unit, 1999 network shares, 2000 years after the Zhuang shares. Therefore, for the Sea King Biology and other recent fry of biomedical stocks, this weekend's "diving", most likely to show the future for a considerable period of silence.　　Therefore, on the one hand, investors are advised to try not to rebound, on the other hand recommended that the investors have been chasing high buy as far as possible to stop. But the recent activity of the biomedical and pharmaceutical stocks, also to investors to bring another revelation, that is, in the new theme of the first a-share market in the early days, can be launched in the beginning of the rapid pursuit of leading stocks, for example, in the context of the news report on the level of disease prevention, sensitive hot money to dig out the biomedical unit, At this time if can quickly intervene to the erecting, the short-term investment return is amazing. In other words, the excessive hype in fact for short-term trend, just like the reverse of the coin, in the beginning of the market, is the opportunity, but once too much hype, is a trap.